David Arkowitz

David A. Arkowitz is currently Director at Yumanity, Inc., Independent Director at iBio, Inc. since 2024, and Chief Financial Officer at Alkeus Pharmaceuticals, Inc. since 2024.
Former positions include Director at ImpactRx, Inc. (2009), Director at Aegerion Pharmaceuticals, Inc. (2009), Director-Financial Planning & Analysis at Merck-Medco Managed Care LLC, Independent Director at Proteostasis Therapeutics, Inc., Independent Director at F-Star Therapeutics, Inc. (2020–2023), Independent Director at Kineta, Inc. (2022–2025), Independent Director at Yumanity Therapeutics, Inc. (2020–2022), VP & Controller-Research & Development Division at Merck & Co., Inc. (2003), Chief Financial Officer & Treasurer at Idenix Pharmaceuticals LLC (2003–2007), Chief Financial Officer & General Manager at Mascoma Corp.
(2011–2013), Chief Financial & Accounting Officer at Flexion Therapeutics, Inc. (2018–2021), Vice President-Finance & Business Development at Merck Frosst Canada Ltd. (2000),.
Controller at Merck Research Laboratories Massachusetts LLC (1990–2003), Chief Financial & Business Officer at AMAG Pharmaceuticals, Inc. (2007–2011), CFO, Executive VP & Head-Business Development at Seres Therapeutics, Inc. (2021–2024), and Chief Operating & Financial Officer at Visterra, Inc. (2013–2018).
Education includes undergraduate studies at Brandeis University and an MBA from Columbia Business School.